CA3135755A1 - Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease - Google Patents

Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease Download PDF

Info

Publication number
CA3135755A1
CA3135755A1 CA3135755A CA3135755A CA3135755A1 CA 3135755 A1 CA3135755 A1 CA 3135755A1 CA 3135755 A CA3135755 A CA 3135755A CA 3135755 A CA3135755 A CA 3135755A CA 3135755 A1 CA3135755 A1 CA 3135755A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
present
membered
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3135755A
Other languages
English (en)
French (fr)
Inventor
Daniel DE ROULET
Johan BARTHOLOMEUS
Shawn Johnstone
Randall Marcelo CHIN
Nicholas Thomas Hertz
Robert Devita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitokinin Inc
Original Assignee
Mitokinin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokinin Inc filed Critical Mitokinin Inc
Publication of CA3135755A1 publication Critical patent/CA3135755A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3135755A 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease Pending CA3135755A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962828995P 2019-04-03 2019-04-03
US62/828,995 2019-04-03
US201962879794P 2019-07-29 2019-07-29
US62/879,794 2019-07-29
US201962933632P 2019-11-11 2019-11-11
US62/933,632 2019-11-11
PCT/US2020/026732 WO2020206363A1 (en) 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Publications (1)

Publication Number Publication Date
CA3135755A1 true CA3135755A1 (en) 2020-10-08

Family

ID=72666280

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3135755A Pending CA3135755A1 (en) 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Country Status (11)

Country Link
US (2) US20220162215A1 (https=)
EP (1) EP3947390A4 (https=)
JP (1) JP2022527025A (https=)
KR (1) KR20220004068A (https=)
CN (1) CN114026093A (https=)
AU (1) AU2020253561A1 (https=)
BR (1) BR112021019802A2 (https=)
CA (1) CA3135755A1 (https=)
IL (1) IL286767A (https=)
MX (1) MX2021012129A (https=)
WO (1) WO2020206363A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018290225A1 (en) 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
US20250129080A1 (en) * 2021-08-20 2025-04-24 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2023023671A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2024040266A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Disubstituted benzoimidazole and indole analogs as modulators of pink1
EP4620957A1 (en) * 2024-03-22 2025-09-24 Eberhard Karls Universität Tübingen Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof
CN118290348A (zh) * 2024-03-22 2024-07-05 诚达药业股份有限公司 一种4-氯吡咯并嘧啶类化合物或其衍生物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
CN101282761A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的苯并咪唑衍生物
ES2412384T3 (es) * 2006-07-18 2013-07-11 Astellas Pharma Inc. Derivado de aminoindano o sal del mismo
WO2014124458A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
ES2919024T3 (es) * 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
AU2018290225A1 (en) * 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN115515682B (zh) * 2020-02-21 2024-06-21 麦托吉宁公司 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法

Also Published As

Publication number Publication date
US20250250276A1 (en) 2025-08-07
MX2021012129A (es) 2022-01-31
KR20220004068A (ko) 2022-01-11
JP2022527025A (ja) 2022-05-27
BR112021019802A2 (pt) 2021-12-07
IL286767A (en) 2021-12-01
EP3947390A1 (en) 2022-02-09
EP3947390A4 (en) 2022-11-30
CN114026093A (zh) 2022-02-08
WO2020206363A1 (en) 2020-10-08
AU2020253561A1 (en) 2021-12-02
US20220162215A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US20250250276A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
JP7849881B2 (ja) 細胞外タンパク質を分解するａｓｇｐｒ結合性化合物
CA2939219C (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN111788182B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
KR20180002730A (ko) 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법
WO2018153507A1 (en) Substituted dihydrobenzofuran glycosidase inhibitors
EP3672958B1 (en) Annulated glycosidase inhibitors
AU2024202745A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
JP7808226B2 (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
US20250129080A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
CN108658976B (zh) 一类新型吡唑并[4,3-c]吡啶-4(5)-酮布鲁顿激酶抑制剂
CA3194653A1 (en) Compositions and methods of treating kidney disease and fibrosis
US20240376111A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2024040266A2 (en) Disubstituted benzoimidazole and indole analogs as modulators of pink1
BR122025016812A2 (pt) Compostos de adeninas, uso dos mesmos, composição farmacêutica, método para modular a atividade da quinase pink1 em um indivíduo, e kit
WO2024040267A2 (en) Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof
CA3164707A1 (en) Combination therapy for treating mps1
HK40086209B (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240403

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250515

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250915

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260127